类淀粉沉积症治疗市场规模、份额及成长分析（按类型、最终用途和地区）－产业预测 2025-2032

2023 年类淀粉沉积症治疗市场规模价值为 58.7 亿美元，预计将从 2024 年的 63.2 亿美元增长到 2032 年的 113.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 7.6%。

全球类淀粉沉积症治疗市场正在经历显着增长，这得益于人们认识的提高、诊断率的提高以及人口老化带来的治疗方案的进步。淀粉样变性的特征是淀粉样蛋白的累积会导致器官功能障碍，类淀粉沉积症已引起人们的关注，并推动了治疗方法的创新，包括化疗、干细胞移植以及单株抗体和小分子抑制剂等尖端标靶治疗。这些新方法可望阻止或逆转疾病进展，促使製药公司在研发方面进行大量投资。儘管面临治疗费用上升以及早期诊断对改善患者预后的重要性等挑战，但随着有效治疗方法的不断涌现，类淀粉沉积症治疗市场预计未来仍将保持成长轨迹。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

类淀粉沉积症治疗市场规模（按类型及复合年增长率）（2025-2032）

• 市场概览
• 治疗方法
  • 化疗
  • 标靶治疗
  • 抗血管新生治疗
  • 单株抗体
  • 蛋白酶体抑制剂
• 外科手术
  • 骨髓/干细胞移植
  • 器官移植

类淀粉沉积症治疗市场规模（按最终用途和复合年增长率） (2025-2032)

• 市场概览
• 医院和诊所
• 门诊手术中心
• 居家照护
• 其他的

类淀粉沉积症治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Alnylam Pharmaceuticals（United States）
• Ionis Pharmaceuticals（United States）
• Intellia Therapeutics（United States）
• Genmab（Denmark）
• Pfizer（United States）
• BridgeBio Pharma（United States）
• Eidos Therapeutics（United States）
• Prothena Corporation（United States）
• Alexion Pharmaceuticals（United States）
• SOM Biotech（Spain）
• Neurimmune（Switzerland）
• Corino Therapeutics（United States）
• Proclara Biosciences（United States）
• Arcturus Therapeutics（United States）
• Dicerna Pharmaceuticals（United States）
• GlaxoSmithKline（United Kingdom）
• Johnson & Johnson（United States）
• Novartis（Switzerland）
• Roche（Switzerland）

结论和建议

Amyloidosis Treatment Market size was valued at USD 5.87 billion in 2023 and is poised to grow from USD 6.32 billion in 2024 to USD 11.35 billion by 2032, growing at a CAGR of 7.6% during the forecast period (2025-2032).

The global amyloidosis treatment market is experiencing notable growth, fueled by rising awareness, improved diagnostic rates, and advancements in therapeutic options amid an aging population. Characterized by the buildup of amyloid proteins causing organ dysfunction, amyloidosis has garnered increased attention, driving innovations in treatment, such as chemotherapy, stem cell transplantation, and cutting-edge targeted therapies like monoclonal antibodies and small molecule inhibitors. These novel approaches are demonstrating potential in halting or reversing disease progression, prompting significant investments in R&D from pharmaceutical companies. Despite challenges like high treatment costs and the critical need for early diagnosis to enhance patient outcomes, the continued emergence of effective therapies suggests that the amyloidosis treatment market will sustain its growth trajectory in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Amyloidosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Amyloidosis Treatment Market Segments Analysis

Global Amyloidosis Treatment Market is segmented by Type, End-use and region. Based on Type, the market is segmented into Medication and Surgery. Based on End-use, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Amyloidosis Treatment Market

The rising incidence of amyloidosis, encompassing both AL amyloidosis and ATTR amyloidosis, serves as a crucial driver for the market. Enhanced awareness and advancements in diagnostic techniques are contributing to an increase in accurate diagnoses, resulting in a larger population of patients who require effective treatment options. As more individuals are identified and confirmed as having this condition, the demand for innovative therapies and comprehensive care is expected to grow significantly, thereby propelling the amyloidosis treatment market forward. This upward trend in patient identification highlights the urgency for improved treatment solutions and fosters ongoing research and development in this field.

Restraints in the Amyloidosis Treatment Market

The amyloidosis treatment market faces significant challenges due to the limited availability of effective treatment options, despite ongoing advancements in research and drug development. Many individuals diagnosed with amyloidosis experience inadequate responses to existing therapies, highlighting the urgent need for more effective solutions. This situation not only hampers patient outcomes but also creates a pressing demand for innovative treatments that can address the unique complexities of the disease. As a result, the market is restrained by the necessity for enhanced therapeutic options that can better meet the needs of patients struggling with this challenging condition.

Market Trends of the Amyloidosis Treatment Market

The amyloidosis treatment market is witnessing a significant shift towards advancements in targeted therapies, driven by intensive research and development. Pharmaceutical companies are increasingly focusing on monoclonal antibodies and small molecules, which aim to inhibit the production and deposition of amyloid proteins characteristic of the disease. This innovative approach seeks to enhance patient outcomes by directly addressing the underlying pathophysiology. Ongoing clinical trials are crucial in evaluating the safety and efficacy of these novel treatments, indicating a promising future for therapeutic options. As these therapies progress towards approval, they are expected to fundamentally redefine the treatment landscape for amyloidosis, creating lucrative opportunities within the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Amyloidosis Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Medication
  • Chemotherapy
  • Targeted therapy
  • Anti-Angiogenesis Therapy
  • Monoclonal Antibodies
  • Proteasome Inhibitors
• Surgery
  • Bone Marrow Transplantation/Stem Cell Transplantation
  • Organ Transplantation

Global Amyloidosis Treatment Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Global Amyloidosis Treatment Market Size & CAGR (2025-2032)

• North America (Type, End-use)
  • US
  • Canada
• Europe (Type, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Alnylam Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eidos Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOM Biotech (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurimmune (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corino Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proclara Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcturus Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations